scholarly journals A Systematic Review and Meta-analysis of Effect of Probiotic Supplementation on Age-related Sarcopenia in Elderly Adults

2021 ◽  
Author(s):  
Sahar Saraf-Bank ◽  
Fatemeh Navab ◽  
Mohammad Hossein Rouhan ◽  
Zahra Hajhashemy ◽  
Nafiseh Shokri-mashhadi
Keyword(s):  
Muscle Strength ◽  
Muscle Mass ◽  
Body Mass ◽  
Positive Impact ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Elderly Subjects ◽  
Probiotic Supplementation ◽  
Anthropometric Indices ◽  
Age Related

Abstract Background: Several clinical studies emphasized the role of bio-diversities of gut microbiota in age-related disorders. Nevertheless, the effect of probiotic administration on sarcopenia indices are unclear. This meta-analysis aimed to investigate the effect of probiotic administration on muscle strength, muscle mass, and muscle function. Methods: We assessed all interventional studies through different electronic databases including PubMed, Scopus, ISI –Web of Science, and Cochrane library using defined keywords from inception to Jun 2021. Studies that investigated the effect of probiotic administration on at least one of the components of sarcopenia or anthropometric indices versus non- probiotics in old adults (>55 years) were included. Results: The initially overall effect of meta-analysis on 1393 participants declared a null effect of probiotic supplementation on main outcomes, including muscle mass (WMD: -0.05, 95% CI: -1.54, 1.43; I-square: 0.0%, P=0.985), and muscle strength (WMD: 0.7, 95% CI: -0.01, 1.40; I-square: 76.8%, P=0.005). Subgroup analysis showed that administration of probiotic supplementation for more than 12 weeks significantly increased muscle strength (WMD: 1.15, 95% CI: 0.86, 1.43; I-square: 0.0%, P=0.679). However, probiotic supplementation had no effect on anthropometric indices, including body mass and body mass index, (WMD: -0.05, 95% CI:-2.57, 1.56; I-square: 0.0%, P=0.976) and (WMD: 0.08, 95% CI:-0.16, 0.32; I-square: 0.0%, P=0.718), respectively. Conclusion: This study confirmed the positive impact of probiotic supplementation on the muscle strength (based on the last definitions by EWGSOP), in particular, probiotic administration for more than 12 weeks. More clinical trials on sarcopenic elderly subjects are wanted to confirm our findings.

scholarly journals Associations between Coenzyme Q10 Status, Oxidative Stress, and Muscle Strength and Endurance in Patients with Osteoarthritis

Antioxidants ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 1275
Author(s):  
Po-Sheng Chang ◽  
Chi-Hua Yen ◽  
Yu-Yun Huang ◽  
Ching-Ju Chiu ◽  
Ping-Ting Lin
Keyword(s):  
Oxidative Stress ◽  
Muscle Strength ◽  
Antioxidant Capacity ◽  
Muscle Mass ◽  
Coenzyme Q10 ◽  
Muscle Function ◽  
Protein Carbonyl ◽  
Elderly Subjects ◽  
Muscle Endurance ◽  
Age Related

Osteoarthritis (OA) causes oxidative stress. Coenzyme Q10 is an antioxidant that participates in energy production in the human body. The purpose of this study was to investigate the relationships among coenzyme Q10 status, oxidative stress, antioxidant capacity, and muscle function in patients with OA. This case-control study recruited 100 patients with OA and 100 without OA. The coenzyme Q10 status, oxidative stress, antioxidant capacity, muscle mass (by dual-energy X-ray absorptiometry), muscle strength (hand-grip and leg-back strength), and muscle endurance (dumbbell curls, gait speed, chair-stand test, and short physical performance battery) were measured. The results showed that both OA and elderly subjects had a low coenzyme Q10 status (<0.5 μM). Oxidative stress was significantly negatively correlated with muscle function (protein carbonyl, p < 0.05). Coenzyme Q10 level was positively associated with antioxidant capacity, muscle mass, muscle strength and muscle endurance in patients with OA (p < 0.05). Since OA is an age-related disease, coenzyme Q10 may be consumed by oxidative stress and thereby affect muscle function. Raising coenzyme Q10 in patients with OA could be suggested, which may benefit their antioxidant capacity and muscle function.

scholarly journals The effectiveness of leucine on muscle protein synthesis, lean body mass and leg lean mass accretion in older people: a systematic review and meta-analysis

2014 ◽  
Vol 113 (1) ◽  
pp. 25-34 ◽  
Author(s):  
Zhe-rong Xu ◽  
Zhong-ju Tan ◽  
Qin Zhang ◽  
Qi-feng Gui ◽  
Yun-mei Yang
Keyword(s):  
Lean Body Mass ◽  
Muscle Mass ◽  
Body Mass ◽  
Lean Mass ◽  
Muscle Protein ◽  
Meta Analysis ◽  
Elderly Subjects ◽  
Leucine Supplementation ◽  
Synthetic Rate ◽  
Fractional Synthetic Rate

In the present study, we performed a meta-analysis to assess the ability of leucine supplementation to increase the muscle protein fraction synthetic rate and to augment lean body mass or leg lean mass in elderly patients. A literature search was conducted on Medline, Cochrane, EMBASE and Google Scholar databases up to 31 December 2013 for clinical trials that investigated the administration of leucine as a nutrient that affects muscle protein metabolism and muscle mass in elderly subjects. The included studies were randomised controlled trials. The primary outcome for the meta-analysis was the protein fractional synthetic rate. Secondary outcomes included lean body mass and leg lean mass. A total of nine studies were included in the meta-analysis. The results showed that the muscle protein fractional synthetic rate after intervention significantly increased in the leucine group compared with the control group (pooled standardised difference in mean changes 1·08, 95 % CI 0·50, 1·67; P< 0·001). No difference was found between the groups in relation to lean body mass (pooled standardised difference in mean changes 0·18, 95 % CI − 0·18, 0·54; P= 0·318) or leg lean mass (pooled standardised difference in mean changes 0·006, 95 % CI − 0·32, 0·44; P= 0·756). These findings suggest that leucine supplementation is useful to address the age-related decline in muscle mass in elderly individuals, as it increases the muscle protein fractional synthetic rate.

Testosterone supplementation on sarcopenia components in chronic patients: a systematic review and meta-analysis

2021 ◽  
Vol 27 ◽  
Author(s):  
Camila Correa ◽  
Patrícia Bieger ◽  
Ingrid S. Perry ◽  
Gabriela C. Souza
Keyword(s):  
Systematic Review ◽  
Chronic Disease ◽  
Muscle Strength ◽  
Muscle Mass ◽  
Muscular Atrophy ◽  
Meta Analysis ◽  
Current Evidence ◽  
Cochrane Library ◽  
Mesh Terms ◽  
Chronic Disease Patients

Background: Sarcopenia is a progressive and generalized skeletal muscle disorder with unfavorable muscle changes throughout life, which can be associated with chronic disease. Testosterone supplementation is emerging as a possible therapy; however, it is still necessary to explore its effectiveness Objectives: This systematic review and meta-analysis aimed to evaluate and summarize the evidence related to the effect of testosterone supplementation on sarcopenia components of chronic disease patients. Methods: We performed a systematic review and meta-analysis with studies that assessed the effect of testosterone supplementation on sarcopenia components of chronic disease patients. Papers were identified using Medical Subject Heading (MeSH) terms, combining “sarcopenia”, “muscular atrophy”, and “testosterone”, searching MEDLINE, EMBASE, and Cochrane Library databases, and also hand searching. Results: The database search resulted in 1602 applicable citations that could be included. Of those, 1560 were removed at the first phase, by reading the title and abstract, and a total of 17 studies were finally included after full-text assessment and manual searches of previous review references. With regard to the effects of testosterone supplementation on sarcopenia components, when taken together, the evaluated studies presented an increase in muscle mass and/or muscle strength, but results for muscle functional capacity were inconsistent. Conclusions: Testosterone supplementation increased the muscle mass and muscle strength in chronic disease patients. However, current evidence does not indicate that those patients could benefit from testosterone supplementation in order to improve their muscle function.

Impact of activity trackers on secondary prevention in patients with coronary artery disease: a systematic review and meta-analysis (Preprint)

2021 ◽  
Author(s):  
Toshiki Kaihara ◽  
Valent Intan-Goey ◽  
Martijn Scherrenberg ◽  
Maarten Falter ◽  
Ines Frederix ◽  
...  
Keyword(s):  
Secondary Prevention ◽  
Positive Impact ◽  
Meta Analysis ◽  
Peak Oxygen Consumption ◽  
Cochrane Library ◽  
Major Adverse Cardiovascular Events ◽  
Cvd Risk ◽  
Activity Tracker ◽  
Activity Trackers ◽  
Peak Vo2

BACKGROUND Ischemic heart disease (IHD) is related to high rates of morbidity and mortality among cardiovascular diseases (CVD). Activity trackers have been used in cardiac rehabilitation (CR) in the last years. However, their effectiveness to influence outcomes after IHD is debated. OBJECTIVE This review summarizes the latest data of impact of activity trackers on CVD risk and outcomes. METHODS Articles from 1986 to 2020 in English were searched by electronic databases (PubMed, Cochrane Library, Embase). Inclusion criteria were: randomized controlled trials of IHD secondary prevention using an activity tracker which include at least peak oxygen consumption (VO2), major adverse cardiovascular events (MACE), quality of life (QoL), LDL-cholesterol (LDL-C) as outcomes. Meta-analysis and qualitative analysis were performed. RESULTS After removing duplicates, 604 articles were included and the screening identified a total of 11 articles. Compared to control groups, intervention groups with activity trackers significantly increased peak VO2 (mean difference 1.54; 95% CI [0.50–2.57]; P=.004) and decreased MACE (risk ratio 0.51; 95% CI [0.31–0.86]; P=.01). Heterogeneity was low (I2=0%) for MACE and high (I2=51%) for peak VO2. Intervention with an activity tracker also has positive impact on QoL in qualitative analyses. There was no between-group difference in LDL-C. CONCLUSIONS CR using activity trackers has a positive and multi-faceted effect on peak VO2, MACE, and QoL in patients with IHD.

scholarly journals A Systematic Review with Meta-Analysis of the Effect of Resistance Training on Whole-Body Muscle Growth in Healthy Adult Males

2020 ◽  
Vol 17 (4) ◽  
pp. 1285 ◽  
Author(s):  
Pedro J. Benito ◽  
Rocío Cupeiro ◽  
Domingo J. Ramos-Campo ◽  
Pedro E. Alcaraz ◽  
Jacobo Á. Rubio-Arias
Keyword(s):  
Systematic Review ◽  
Resistance Training ◽  
Muscle Mass ◽  
Meta Analysis ◽  
Muscle Growth ◽  
Fat Free Mass ◽  
Muscle Size ◽  
Whole Body ◽  
Cochrane Library ◽  
Significant Variable

We performed a systematic review and meta-analysis to study all published clinical trial interventions, determined the magnitude of whole-body hypertrophy in humans (healthy males) and observed the individual responsibility of each variable in muscle growth after resistance training (RT). Searches were conducted in PubMed, Web of Science and the Cochrane Library from database inception until 10 May 2018 for original articles assessing the effects of RT on muscle size after interventions of more than 2 weeks of duration. Specifically, we obtain the variables fat-free mass (FMM), lean muscle mass (LMM) and skeletal muscle mass (SMM). The effects on outcomes were expressed as mean differences (MD) and a random-effects meta-analysis and meta-regressions determined covariates (age, weight, height, durations in weeks…) to explore the moderate effect related to the participants and characteristics of training. One hundred and eleven studies (158 groups, 1927 participants) reported on the effects of RT for muscle mass. RT significantly increased muscle mass (FFM+LMM+SMM; Δ1.53 kg; 95% CI [1.30, 1.76], p < 0.001; I2 = 0%, p = 1.00). Considering the overall effects of the meta-regression, and taking into account the participants’ characteristics, none of the studied covariates explained any effect on changes in muscle mass. Regarding the training characteristics, the only significant variable that explained the variance of the hypertrophy was the sets per workout, showing a significant negative interaction (MD; estimate: 1.85, 95% CI [1.45, 2.25], p < 0.001; moderator: -0.03 95% CI [−0.05, −0.001] p = 0.04). In conclusion, RT has a significant effect on the improvement of hypertrophy (~1.5 kg). The excessive sets per workout affects negatively the muscle mass gain.

Modeling the blood lactate kinetics at maximal short-term exercise conditions in children, adolescents, and adults

2005 ◽  
Vol 99 (2) ◽  
pp. 499-504 ◽  
Author(s):  
Ralph Beneke ◽  
Matthias Hütler ◽  
Marcus Jung ◽  
Renate M. Leithäuser
Keyword(s):  
Blood Lactate ◽  
Muscle Mass ◽  
Body Mass ◽  
Short Term ◽  
Wingate Anaerobic Test ◽  
Blood Compartment ◽  
Test Conditions ◽  
Age Related ◽  
Adolescents And Adults ◽  
Anaerobic Test

Whether age-related differences in blood lactate concentrations (BLC) reflect specific BLC kinetics was analyzed in 15 prepubescent boys (age 12.0 ± 0.6 yr, height 1.54 ± 0.06 m, body mass 40.0 ± 5.2 kg), 12 adolescents (16.3 ± 0.7 yr, 1.83 ± 0.07 m, 68.2 ± 7.5 kg), and 12 adults (27.2 ± 4.5 yr, 1.83 ± 0.06 m, 81.6 ± 6.9 kg) by use of a biexponential four-parameter kinetics model under Wingate Anaerobic Test conditions. The model predicts the lactate generated in the extravasal compartment (A), invasion ( k1), and evasion ( k2) of lactate into and out of the blood compartment, the BLC maximum (BLCmax), and corresponding time (TBLCmax). BLCmax and TBLCmax were lower ( P < 0.05) in boys (BLCmax 10.2 ± 1.3 mmol/l, TBLCmax 4.1 ± 0.4 min) than in adolescents (12.7 ± 1.0 mmol/l, 5.5 ± 0.7 min) and adults (13.7 ± 1.4 mmol/l, 5.7 ± 1.1 min). No differences were found in A related to the muscle mass (AMM) and k1 between boys (AMM: 22.8 ± 2.7 mmol/l, k1: 0.865 ± 0.115 min−1), adolescents (22.7 ± 1.3 mmol/l, 0.692 ± 0.221 min−1), and adults (24.7 ± 2.8 mmol/l, 0.687 ± 0.287 min−1). The k2 was higher ( P < 0.01) in boys (2.87 10−2 ± 0.75 10−2 min−1) than in adolescents (2.03 × 10−2 ± 0.89 × 10−2 min−1) and adults (1.99 × 10−2 ± 0.93 × 10−2 min−1). Age-related differences in the BLC kinetics are unlikely to reflect differences in muscular lactate or lactate invasion but partly faster elimination out of the blood compartment.

scholarly journals Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Jianqing Li ◽  
Jiayi Xu ◽  
Yiyi Chen ◽  
Jiaju Zhang ◽  
Yihong Cao ◽  
...  
Keyword(s):  
Systematic Review ◽  
Macular Degeneration ◽  
Meta Analysis ◽  
Age Related Macular Degeneration ◽  
Cochrane Library ◽  
Anti Vegf ◽  
Age Related ◽  
Significant Difference ◽  
The Mean

Purpose. Intravitreal antivascular endothelial growth factor (anti-VEGF) therapy has been widely used for the treatment of neovascularization (NV) secondary to age-related macular degeneration (AMD). This study aimed to compare the efficacy among different subtypes of neovascular age-related macular degeneration (nAMD). Methods. PubMed, Embase, and the Cochrane Library were searched for eligible studies. We performed meta-analysis using Review Manager 5.3 and Stata/SE 12.0. Results. A total of 24 studies met our inclusion criteria and were included in the systematic review. At 3 months, the mean logarithm of the minimum angle of resolution (logMAR) improvements were −0.09, −0.18, and −0.23 for type 1, 2, and 3, respectively, while the mean macular thickness (MT) changes were −104.83, −130.76, and −196.29 μm. At 12 months, the mean changes in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters were 6.38, 8.12, and 9.37, while the MT decrease was 126.51, 126.52, and 139.85 μm, respectively. However, statistically significant difference was only found between type 1 and 3 in vision improvement, both in the short term (p=0.0002) and long term (p=0.01). Conclusions. The reactivity to VEGF inhibitors varied among different subtypes of nAMD. The efficacy of intravitreal anti-VEGF therapy in type 3 nAMD was statistically better than type 1 when considering vision improvement at 3 and 12 months. Thus, the lesion subtype is a predictor for the treatment outcome which can help guide prognosis.

scholarly journals Effects of vibration therapy on muscle mass, muscle strength and physical function in older adults with sarcopenia: a systematic review and meta-analysis

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Shuang Wu ◽  
Hong-Ting Ning ◽  
Su-Mei Xiao ◽  
Ming-Yue Hu ◽  
Xin-Yin Wu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Older Adults ◽  
Muscle Strength ◽  
Physical Function ◽  
Muscle Mass ◽  
Meta Analysis ◽  
Whole Body Vibration ◽  
Whole Body ◽  
Local Vibration ◽  
Vibration Therapy

Abstract Background Sarcopenia, a progressive loss of muscle mass and function with advancing age, is a prevalent condition among older adults. As most older people are too frail to do intensive exercise and vibration therapy has low risk and ease of participation, it may be more readily accepted by elderly individuals. However, it remains unclear whether vibration therapy would be effective among older adults with sarcopenia. This systematic review and meta-analysis examined the effect of vibration therapy including local vibration therapy and whole-body vibration therapy, for enhancing muscle mass, muscle strength and physical function in older people with sarcopenia. Methods A systematic literature search was conducted in March 2019 in the following 5 electronic databases: PubMed, CINAHL, Embase, PEDro, and the Cochrane Central Register of Controlled Trials, with no restriction of language or the year of publication. Randomized controlled trials and quasi-experimental studies examining effects of vibration therapy on muscle mass, muscle strength or physical function in older adults with sarcopenia were included in this systematic review. Two reviewers independently assessed the methodological quality of the selected studies. Results Of the 1972 identified studies, seven publications from six studies involving 223 participants were included in this systematic review. Five of them conducted whole-body vibration therapy, while two conducted local vibration therapy. A meta-analysis of randomized controlled studies indicated that muscle strength significantly increased after whole-body vibration therapy (SMD 0.69, 95% CI 0.28 to 1.11, I2 = 0%, P = 0.001) and local vibration therapy (SMD 3.78, 95% CI 2.29 to 5.28, P < 0.001). Physical performance measured by the sit-to-stand test and the timed-up-and-go test were significantly improved after the intervention (SMD -0.79, 95% CI − 1.21 to − 0.37, I2 = 0%, P < 0.001) and SMD -0.83, 95% CI − 1.56 to − 0.11, I2 = 64%, P = 0.02, respectively). Conclusion Vibration therapy could be a prospective strategy for improving muscle strength and physical performance in older adults with sarcopenia. However, due to the limited number of the included studies, caution is needed when interpreting these results. More well-designed, large sample size studies should be conducted to further explore and validate the benefits of vibration therapy for this population.

scholarly journals Plasma Transthyretin as A Biomarker of Sarcopenia in Elderly Subjects

Nutrients ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 895 ◽  
Author(s):  
Yves Ingenbleek
Keyword(s):  
Muscle Mass ◽  
Body Mass ◽  
Fatal Outcome ◽  
Good Health ◽  
The Body ◽  
Nutritional Deficiencies ◽  
Elderly Subjects ◽  
Elderly Persons ◽  
Inflammatory Disorders ◽  
Screening Programs

Skeletal muscle (SM) mass, the chief component of the structural compartment belonging to lean body mass (LBM), undergoes sarcopenia with increasing age. Decreased SM in elderly persons is a naturally occurring process that may be accelerated by acute or chronic nutritional deficiencies and/or inflammatory disorders, declining processes associated with harmful complications. A recently published position paper by European experts has provided an overall survey on the definition and diagnosis of sarcopenia in elderly persons. The present review describes the additional contributory role played by the noninvasive transthyretin (TTR) micromethod. The body mass index (BMI) formula is currently used in clinical studies as a criterion of good health to detect, prevent, and follow up on the downward trend of muscle mass. The recent upsurge of sarcopenic obesity with its multiple subclasses has led to a confused stratification of SM and fat stores, prompting workers to eliminate BMI from screening programs. As a result, investigators are now focusing on indices of protein status that participate in SM growth, maturation, and catabolism that might serve to identify sarcopenia trajectories. Plasma TTR is clearly superior to all other hepatic biomarkers, showing the same evolutionary patterns as those displayed in health and disease by both visceral and structural LBM compartments. As a result, this TTR parameter maintains positive correlations with muscle mass downsizing in elderly persons. The liver synthesis of TTR is downregulated in protein-depleted states and suppressed in cytokine-induced inflammatory disorders. TTR integrates the centrally-mediated regulatory mechanisms governing the balance between protein accretion and protein breakdown, emerging as the ultimate indicator of LBM resources. This review proposes the adoption of a gray zone defined by cut-off values ranging from 200 mg/L to 100 mg/L between which TTR plasma values may fluctuate and predict either the best or the worst outcome. The best outcome occurs when appropriate dietary, medicinal and surgical decisions are undertaken, resuming TTR synthesis which manifests rising trends towards pre-stress levels. The worst occurs when all therapeutic means fail to succeed, leading inevitably to complete exhaustion of LBM and SM metabolic resources with an ensuing fatal outcome. Some patients may remain unresponsive in the middle of the gray area, combining steady clinical states with persistent stagnant TTR values. Using the serial measurement of plasma TTR values, these last patients should be treated with the most aggressive and appropriate therapeutic strategies to ensure the best outcome.

scholarly journals The Effect of Kinesitherapy on Bone Mineral Density in Primary Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Shanxi Wang ◽  
Shuzhen Li ◽  
Xing Xie ◽  
Juying Xie
Keyword(s):  
Lumbar Spine ◽  
Femoral Neck ◽  
Controlled Trial ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Primary Osteoporosis ◽  
Mineral Density ◽  
Age Related ◽  
Positive Effect ◽  
Quality Evidence

Objective. Osteoporosis (OP) is a well-established age-related disease, pathologically characterized by bone microarchitectural deterioration, increased fragility, and low BMD. Primary osteoporosis (POP) is the most common type of OP. Methods. Publications pertaining to the effectiveness of kinesitherapy on BMD in POP from PubMed, SCI, Cochrane Library, Embase, VIP, CNKI, and Wanfang Database were retrieved from their inception to October 2019. Results. A total of 21 studies with 1840 participants were included. The results of the meta-analysis revealed that kinesitherapy plus antiosteoporosis medications had a positive effect on lumbar spine BMD when the duration of intervention was 6 months (MD = 0.11 g/cm2; 95% CI: 0.06–0.15; P<0.0001) or >6 months (MD = 0.04 g/cm2; 95% CI: 0.02–0.06; P<0.0001) compared with antiosteoporosis medications alone. Additional kinesitherapy plus antiosteoporosis medications were associated with improved femoral neck BMD compared with antiosteoporosis medications alone (MD = 0.09 g/cm2; 95% CI: 0.03–0.16; P=0.004). Conclusions. Kinesitherapy plus antiosteoporosis medications significantly improved lumbar spine and femoral neck BMD in the current low-quality evidence. Additional high-quality evidence is required to confirm the effect of kinesitherapy on BMD in patients with POP.

Sign in / Sign up

Export Citation Format

Share Document